Latest Trials Latest NewsFAQ

GILEAD SCIENCES SL

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults

Phase 4

Completed

Conditions: HIV-1 Infection

Interventions: Drug: TVD
Drug: ATR
Drug: STB
Drug: RTV
Drug: ATV
Drug: ABC/3TC
Drug: Iohexol

First Posted Date: 2014-09-23

Last Posted Date: 2018-01-03

Lead Sponsor: Gilead Sciences

Target Recruit Count: 72

Registration Number: NCT02246998

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Phase 1

Completed

Conditions: Marginal Zone Lymphoma
Chronic Lymphocytic Leukemia
Indolent Non-Hodgkin Lymphoma
Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia)
Follicular Lymphoma
Small Lymphocytic Lymphoma

Interventions: Drug: Idelalisib

First Posted Date: 2014-09-16

Last Posted Date: 2021-03-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 6

Registration Number: NCT02242045

Selonsertib in Adults With Pulmonary Arterial Hypertension

Phase 2

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Placebo
Drug: Selonsertib

First Posted Date: 2014-09-09

Last Posted Date: 2019-04-10

Lead Sponsor: Gilead Sciences

Target Recruit Count: 151

Registration Number: NCT02234141

Locations: 🇺🇸
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
🇨🇦
University Health Network, Toronto, Ontario, Canada
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

and more 43 locations

Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis

Phase 2

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: LDV/SOF
Drug: VDV
Drug: RBV

First Posted Date: 2014-08-27

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 47

Registration Number: NCT02226549

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection

Phase 3

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF/VEL
Drug: SOF
Drug: RBV

First Posted Date: 2014-08-20

Last Posted Date: 2018-11-15

Lead Sponsor: Gilead Sciences

Target Recruit Count: 269

Registration Number: NCT02220998

Locations: 🇺🇸
Emory university, Atlanta, Georgia, United States

Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection

Phase 2

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: LDV/SOF
Drug: Placebo

First Posted Date: 2014-08-19

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 40

Registration Number: NCT02219685

Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: Hu5F9-G4

First Posted Date: 2014-08-15

Last Posted Date: 2019-02-05

Lead Sponsor: Gilead Sciences

Target Recruit Count: 88

Registration Number: NCT02216409

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States

and more 3 locations

Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Adults

Phase 1

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: GS-5745 SC
Drug: GS-5745 IV

First Posted Date: 2014-08-06

Last Posted Date: 2014-10-27

Lead Sponsor: Gilead Sciences

Target Recruit Count: 28

Registration Number: NCT02209987

Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection

Phase 2

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: LDV/SOF
Drug: SOF/VEL
Drug: RBV
Drug: VOX

First Posted Date: 2014-07-29

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 273

Registration Number: NCT02202980

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection

Phase 3

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF/VEL
Drug: SOF
Drug: RBV

First Posted Date: 2014-07-28

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 558

Registration Number: NCT02201953

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy